0

Close
 
Upcoming Allied Market Research
2023
Chronic Pain Management Drugs Market

Chronic Pain Management Drugs Market

by Product Type (Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Opioids, Non-narcotic Analgesic, Antimigraine Agents), by Prescription Type (Prescribed, Over The counter (OTC)) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13319
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Chronic Pain Management Drugs Market

Request Now !

Chronic pain is a complex medical condition that affects the physical and mental activity of the person. It can be caused by trauma, tissue damage, intense exercise, or cancer pain. Chronic pain varies in intensity from person to person. Chronic pain-controlled medications help people in reducing the intensity of their pain. These drugs target the specific biomolecules in the body and alter the specific mechanism to reduce the pain sensation. Treatment is provided to the patient on the basis of cause of pain. Moreover, chronic pain can be managed using various pharmacological and non-pharmacological therapies. Oxycodone, Tramadol, Methadone, Buprenorphine, OxyContin, and other drugs are used in the treatment of chronic pain.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that first emerged in late December in Hubei province of the Wuhan city in China. The virus that causes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious and is transmitted from person to person. Since the outbreak in December 2019, the disease has spread to almost 213 countries across the globe with the World Health Organization declaring it a pandemic on March 11, 2020.

Pharmaceutical and biotech companies along with governments around the globe are working to address the COVID-19 outbreak, from supporting the vaccines development to medicine supply chain planning. Approximately around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a significant increase in demand for the treatment of COVID-19. Such increased demand for these drugs has offered huge opportunities for manufacturers of COVID-19 treatment drugs, as many developed countries are experiencing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future due to the demand for vaccine and the treatment drugs for COVID-19. This is expected to have a significant impact on the chronic pain management drugs market.

Top Impacting Factors

  • Rise in chronic pain cases, surge in geriatric population, increase in number of accidents, rise in cases of cancer & diabetic neuropathy, increase in surgery & post-surgical pain and rise in demand for effective pain treatment are the key factors that drive the growth of the chronic pain management drugs market.
  • Furthermore, increase in adoption of pain management, surge in health care expenses, rise in demand for minimally invasive treatments, increased awareness toward pain management treatments, R&D activities to improve drugs quality & the launch of novel drugs, and joint ventures, agreements & mergers among the key market players drive the growth of the chronic pain management drugs market.
  • However, side effects associated with the use of these drugs such as hypersensitivity and the availability of substitutes limit the market growth.
  • Government initiatives for regulatory approvals are expected to offer lucrative opportunities for the market expansion.

Market Trends

R&D Activities for the Launch of Novel Drugs for Treatment

In 2021, the University of Michigan School of Dentistry confirmed that naltrexone in low doses was an effective treatment for chronic pain. The drug will be available in tablet doses ranging from 50 to100 mg.

In 2021, a university of Rochester researcher, worked on a new drug Tanezumab. These drugs were used to treat chronic lower back pain.

In 2021, Nektar completed clinical trials on NKTR-181 and applied to the FDA for approval of the drug which was used in the treatment of chronic pain.

Key Benefits of the Report

  • This study presents the analytical depiction of chronic pain management drugs market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the chronic pain management drugs market.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and the competition that will take shape in coming years.

Questions Answered in the Chronic Pain Management Drugs Market Report     

  • Who are the leading market players active in the chronic pain management drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the future projections that would help in taking further strategic steps?
  • What is "chronic pain management drugs"?
  • What is the prediction of the "chronic pain management" market in the future?
  • Who are the leading global market players in the "chronic pain management drugs" market?
  • What are the current and predicted trends?
  • What are the key benefits of the "chronic pain management drugs" market report?

 Chronic Pain Management Drugs Market Report Highlights

Aspects Details
By Product Type
  • Anticonvulsants
  • Antidepressants
  • Anesthetics
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Opioids
  • Non-narcotic Analgesic
  • Antimigraine Agents
By Prescription Type
  • Prescribed
  • Over The counter (OTC)
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Endo International plc., AstraZeneca plc., Novartis AG, Depomed Inc., Johnson and Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Merck & Co., GlaxoSmithKline plc., Purdue Pharma L.P., Pfizer Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Anticonvulsants

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Antidepressants

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Anesthetics

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Opioids

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Non-narcotic Analgesic

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Antimigraine Agents

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY PRESCRIPTION TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Prescription Type

    • 5.2. Prescribed

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Over The Counter (OTC)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Prescription Type

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Chronic Pain Management Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Prescription Type
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Chronic Pain Management Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Prescription Type
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Chronic Pain Management Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Prescription Type
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Prescription Type

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Chronic Pain Management Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Prescription Type
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Chronic Pain Management Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Prescription Type
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Chronic Pain Management Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Prescription Type
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Chronic Pain Management Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Prescription Type
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Chronic Pain Management Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Prescription Type
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Chronic Pain Management Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Prescription Type
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Chronic Pain Management Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Prescription Type
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Prescription Type

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Chronic Pain Management Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Prescription Type
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Chronic Pain Management Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Prescription Type
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Chronic Pain Management Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Prescription Type
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Chronic Pain Management Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Prescription Type
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Chronic Pain Management Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Prescription Type
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Chronic Pain Management Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Prescription Type
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Chronic Pain Management Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Prescription Type
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Chronic Pain Management Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Prescription Type
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Chronic Pain Management Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Prescription Type
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Prescription Type

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Chronic Pain Management Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Prescription Type
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Chronic Pain Management Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Prescription Type
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Chronic Pain Management Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Prescription Type
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Chronic Pain Management Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Prescription Type
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Chronic Pain Management Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Prescription Type
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Chronic Pain Management Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Prescription Type
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Pfizer Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Depomed Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Endo International Plc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Purdue Pharma L.P.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Novartis AG

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. AstraZeneca Plc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Johnson And Johnson Services Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Merck And Co.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Abbott Laboratories

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. GlaxoSmithKline Plc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Teva Pharmaceutical Industries Ltd.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR NON-NARCOTIC ANALGESIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTIMIGRAINE AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR PRESCRIBED, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR OVER THE COUNTER (OTC), BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA CHRONIC PAIN MANAGEMENT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. U.S. CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. CANADA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. UK CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. UK CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 48. UK CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. CHINA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 61. CHINA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. INDIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. INDIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 67. INDIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. UAE CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. UAE CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 101. UAE CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA CHRONIC PAIN MANAGEMENT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. PFIZER INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 112. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. DEPOMED INC.: KEY EXECUTIVES
  • TABLE 114. DEPOMED INC.: COMPANY SNAPSHOT
  • TABLE 115. DEPOMED INC.: OPERATING SEGMENTS
  • TABLE 116. DEPOMED INC.: PRODUCT PORTFOLIO
  • TABLE 117. DEPOMED INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ENDO INTERNATIONAL PLC.: KEY EXECUTIVES
  • TABLE 119. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
  • TABLE 120. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
  • TABLE 121. ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO
  • TABLE 122. ENDO INTERNATIONAL PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. PURDUE PHARMA L.P.: KEY EXECUTIVES
  • TABLE 124. PURDUE PHARMA L.P.: COMPANY SNAPSHOT
  • TABLE 125. PURDUE PHARMA L.P.: OPERATING SEGMENTS
  • TABLE 126. PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
  • TABLE 127. PURDUE PHARMA L.P.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 129. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 130. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 131. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 132. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. ASTRAZENECA PLC.: KEY EXECUTIVES
  • TABLE 134. ASTRAZENECA PLC.: COMPANY SNAPSHOT
  • TABLE 135. ASTRAZENECA PLC.: OPERATING SEGMENTS
  • TABLE 136. ASTRAZENECA PLC.: PRODUCT PORTFOLIO
  • TABLE 137. ASTRAZENECA PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. JOHNSON AND JOHNSON SERVICES INC.: KEY EXECUTIVES
  • TABLE 139. JOHNSON AND JOHNSON SERVICES INC.: COMPANY SNAPSHOT
  • TABLE 140. JOHNSON AND JOHNSON SERVICES INC.: OPERATING SEGMENTS
  • TABLE 141. JOHNSON AND JOHNSON SERVICES INC.: PRODUCT PORTFOLIO
  • TABLE 142. JOHNSON AND JOHNSON SERVICES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 144. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 145. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 146. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 147. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 149. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 150. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 151. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 152. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 154. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 155. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 156. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 157. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 159. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 160. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 161. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 162. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHRONIC PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 3. SEGMENTATION CHRONIC PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHRONIC PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHRONIC PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 11. CHRONIC PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR NON-NARCOTIC ANALGESIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ANTIMIGRAINE AGENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. CHRONIC PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY PRESCRIPTION TYPE
  • FIGURE 20. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR PRESCRIBED, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR OVER THE COUNTER (OTC), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CHRONIC PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 23. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. CHRONIC PAIN MANAGEMENT DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: CHRONIC PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. DEPOMED INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. DEPOMED INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. DEPOMED INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ENDO INTERNATIONAL PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. PURDUE PHARMA L.P.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. PURDUE PHARMA L.P.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. PURDUE PHARMA L.P.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. ASTRAZENECA PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ASTRAZENECA PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. ASTRAZENECA PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. JOHNSON AND JOHNSON SERVICES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. JOHNSON AND JOHNSON SERVICES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. JOHNSON AND JOHNSON SERVICES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. MERCK AND CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. MERCK AND CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Chronic Pain Management Drugs Market

Start reading.
This Report and over 68,075+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers